---
title: In Vitro Functionality and Endurance of GMP-Compliant Point-of-Care BCMA.CAR-T
  Cells at Different Timepoints of Cryopreservation
date: '2024-02-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38338672/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240210170637&v=2.18.0
source: heidelberg[Affiliation]
description: The search for target antigens for CAR-T cell therapy against multiple
  myeloma defined the B-cell maturation antigen (BCMA) as an interesting candidate.
  Several studies with BCMA-directed CAR-T cell therapy showed promising results.
  Second-generation point-of-care BCMA.CAR-T cells were manufactured to be of a GMP
  (good manufacturing practice) standard using the CliniMACS Prodigy^(®) device. Cytokine
  release in BCMA.CAR-T cells after stimulation with BCMA positive versus negative
  myeloma ...
disable_comments: true
---
The search for target antigens for CAR-T cell therapy against multiple myeloma defined the B-cell maturation antigen (BCMA) as an interesting candidate. Several studies with BCMA-directed CAR-T cell therapy showed promising results. Second-generation point-of-care BCMA.CAR-T cells were manufactured to be of a GMP (good manufacturing practice) standard using the CliniMACS Prodigy^(®) device. Cytokine release in BCMA.CAR-T cells after stimulation with BCMA positive versus negative myeloma ...